AVR

Anteris is a pre-revenue structural heart company whose FY2025 financials read like a clinical-stage biotech, not an operating business: $1.91M of revenue (down 29.2% YoY) against a $94.1M net loss and $77.8M of operating cash burn. R&D alone ($69.1M) is ~36x revenue, and the accumulated deficit has reached $370.5M. Stockholders' equity has collapsed to essentially zero (-$93K, down from a positive base a year ago), and total assets fell 71.5% to $23.0M while liabilities grew 29%. By any conventional fundamentals lens this is a melting ice cube — the operating margin is -4,908% and the company explicitly warns it 'expect[s] to continue to incur additional losses for the foreseeable future.'

The entire investment case rests on a single asset: the DurAVR THV System, a biomimetic balloon-expandable aortic valve. The MD&A confirms only ~130 patients have been implanted to date, with the pivotal PARADIGM Trial just initiated — first European approval came in October 2025 (Denmark), and the FDA granted IDE approval in November 2025 for a staged enrollment of the first 200 patients. Commercial approval is years away, and the Risk Factors are blunt: 'It is possible that none of our products will be successfully commercialized.'